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of similar structural and pharmacologic characteristics, such as fen-
fluramine and dexfenfluramine (brand names Ponderal®, Isomeride®; 
Servier, Redux®; Wyeth) have been withdrawn from the world 
market since 1997. Indeed, these compounds, derived from the 
amphetamines, are known to be responsible for pulmonary arterial 
hypertension (PAH) and valvular heart disease (VHD). Subsequent 
studies published in 2000 have shown the determinant role of their 
common active metabolite, norfenfluramine, which is present at 
equal plasma concentrations after fenfluramine, dexfenfluramine, 
or benfluorex intake at recommended dosages. Norfenfluramine 
induces VHD and PAH by stimulation of a serotonin receptor sub-
type, expressed on both aortic and mitral valve leaflets as well as in 
pulmonary arteries.
Despite several case reports stressing the association of PAH 
and/or VHD with benfluorex exposure, benfluorex remained avail-
able in France until November 2009. Our initial case-control study 
published in 2010 put forward the toxicity and the VHD risk of 
benfluorex, thus leading to the withdrawal of benfluorex from the 
European and world market, respectively. This pilot study opened 
the avenue to further pharmacoepidemiologic studies validating 
our results and giving detailed data on the benfluorex risks in larger 
populations.
Actual human consequences of longer than 33 years of marketing 
authorization of benfluorex on patients only in France are estimated 
at ~1300 to 1800 deaths and 3100 to 4200 VHD-related hospitali-
zations. To date, there is no estimation of worldwide mortality due 
to benfluorex use.
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TReaTing RaRe inboRn eRRoRs of 
meTabolism: fRom TheoRy To pRacTice
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Summary: Recent public discussion on new treatment options in 
orphan diseases has focused on the great promise they hold, as well 
as the high cost they generate for our health systems. Instead, this 
presentation will consider new facts and difficulties arising from these 
treatments from a purely medical standpoint and discuss some of 
them using examples from our daily practice.
Enzyme-replacement therapy (ERT) for certain lysosomal stor-
age disorders (LSD) does not cross the blood-brain barrier (BBB) 
and does not, therefore, influence disease progression in the brain. 
How should we take into account the extent and speed of progress 
of lysosomal brain disease? Even at the peripheral level, definition 
of satisfactory treatment, efficacy is not straightforward. Miglustat, 
an example for substrate reduction therapy, has the advantage to 
cross the BBB. Recently, it has been used in several neuronopathic 
LSD, including early-manifesting Gaucher type III disease. What is 
the impact of inhibiting the synthesis of complex molecules in a brain 
that is still under construction? What benefice can be expected and 
at what age?
Sapropterin (Kuvan®) is a pharmacologic chaperone that has 
recently been introduced for the treatment of phenylketonuria. There 
is, however, a wide interindividual variation of response to this drug; 
it can in only rare instances completely replace the equally or more 
effective dietary treatment. Treatment policies vary among countries 
and even within countries.
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Summary: At least 6 members of the family of the transient receptor 
potential (TRP) channels are expressed in defined subpopulations of 
primary sensory neurons (nociceptors), where they mediate acute 
nociceptive responses and contribute to allodynic and hyperalgesic 
conditions. Most prominent channels are the vanilloid 1 (TRPV1), 
which is activated by capsaicin, protons, and certain eicosanoids, 
and the ankyrin 1 (TRPA1). TRPA1 is uniquely gated by an unprece-
dented series of reactive exogenous (mustard oil, cinnamaldehyde and 
others) and endogenous molecules. These latter molecules include 
byproducts of oxidative stress, as hydrogen peroxide, 4-hydroxynon-
enal, oxononenal, and many others electrophilic agonists, which, 
by binding to key cysteine residues, cause channel activation and 
nociceptor stimulation. All TRPA1-expressing neurons and the 
majority of TRPV1-expressing neurons express and release sensory 
neuropeptides, which mediate neurogenic inflammatory responses. 
Calcitonin gene–related peptide (CGRP) released from perivascu-
lar trigeminal nerve endings upon TRPV1 or TRPA1 stimulation 
has been now recognized as a major contributing factor of migraine 
headaches. A series of agents, known to trigger migraine attacks, 
have been identified as selective stimulants of TRPV1 or TRPA1, 
thereby producing CGRP-dependent meningeal vasodilatation. There 
is growing evidence that TRPV1 and, even at a larger extent, TRPA1 
contribute to thermal and mechanical hypersensitivity in models of 
inflammatory and neuropathic pain. In particular, recent findings 
underscore the critical role of TRPA1 in models of chemotherapeutic-
induced peripheral neuropathy. The desensitizing action on noci-
ceptor function of topical and repeated application of the TRPV1 
agonist, capsaicin, has been used for a long time for the treatment of 
pain in postherpetic neuralgia and in diabetic neuropathy. In contrast, 
clinical development of TRPV1 antagonists has been hampered by 
unexpected evidence obtained in Phase I studies of their ability to 
increase body temperature and heat pain threshold. The underlying 
hypothesis that TRPA1 plays a major role in pain associated with 
increases in oxidative stress is boosting major efforts in the discovery 
and development of TRPA1 antagonists.
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Summary: Knowledge of the driving molecular abnormalities 
that underlie the malignant phenotype has afforded opportunity 
to pharmacologically, and with surgical precision, target cancers. 
Historically, therapy for hematologic malignancies has been associ-
ated with toxicity to normal bone marrow and lymphoid progeni-
tors. This results in myelosuppression and immunosuppression. The 
discovery of the Philadelphia chromosome t (9:22) and subsequent 
clarification that t (9:22)(q34:q11) resulted in the expression of the 
chimeric growth–promoting protein BCR-ABL led to the development 
clinical Therapeutics
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of imatinib. The anti–CD-20 antibody rituximab led the way for 
immunologic therapeutic approaches for lymphoid malignancies. The 
paradigm of targeting malignancies with increasing greater therapeu-
tic windows is being expanded by both novel agents but also novel 
delivery systems. Furthermore, the next generation of targeting agents 
affords opportunity to minimize host toxicity and increase the likeli-
hood of therapeutic response by targeting specific molecular subsets 
of a single disease. This targeted approach is personalized medicine 
at its best. This presentation will review the history of successes in 
targeted therapy and look to the future for the next generation of 
personalized approaches for hematologic malignancies.
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Summary: Health economic evaluations are central to decisions on 
the availability of new treatments and other health care interventions 
in several jurisdictions across Europe. Health technologies are not 
approved for use in the United Kingdom if they are considered to rep-
resent poor value for money; that is, if their cost-effectiveness exceeds 
around £30,000 (€ 40,000) per quality-adjusted life-year. Personalized 
medicine, in which treatments are prescribed according to patients’ 
characteristics, holds promise for more favorable health outcomes. 
However, as pharmaceutical market shares are potentially reduced as 
a consequence, there is uncertainty as to whether the compensatory 
price adjustments result in cost-effective treatment strategies. It is 
necessary, therefore, to conduct stratified cost-effectiveness analyses 
of treatments based on prognostic factors that reveal populations in 
which treatments are most likely to be effective or less likely to be 
harmful. The cost-effectiveness of pre-prescription genotyping is illus-
trated using a series of case studies: (1) HLA-B*5701 testing, which 
has dramatically reduced the incidence of hypersensitivity reactions 
to abacavir in patients with HIV; (2) VKORC1 and CYP2C9 geno-
typing to guide dose selection with warfarin; (3) HLA-A*3101 testing 
for the reduction in the incidence of carbamazepine-induced cutane-
ous adverse drug reactions; (4) testing for genetic polymorphisms in 
UGT1A1 and irinotecan-induced neutropenia and diarrhea; and (5) 
CYP2C19 testing before clopidogrel treatment in patients with acute 
coronary syndrome. With the exception of abacavir, a specific limita-
tion of these analyses, which introduces considerable uncertainty to 
the estimation of cost-effectiveness, relates to the evidential standards 
for demonstration of the clinical effectiveness of tests.
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Summary: Drug safety is an essential element for the successful oper-
ation and efficiency of any health care system. In the last decade, 
Nigeria—like most emerging countries—has put in place structures 
and mechanisms to ensure the safety of medicines used by its large 
population of ~170 million. Before this period, the focus was mainly 
on the comprehensive registration of medicines as well as ensur-
ing that good quality medicines are allowed into circulation. The 
proportion of substandard/counterfeit medicines in the market has 
decreased significantly.
In 2004, Nigeria was admitted into the WHO International Drug 
Monitoring Scheme as its 74th member after initial pharmacovigilance 
(PV) activities in a number of locations in the country. Its PV system is 
based on voluntary spontaneous reporting of adverse drug reactions. 
The operating system is the Vigiflow linked to the Uppsala Monitoring 
Centre and currently holds > 10,000 ICSRs in its local database. The 
country has recently set up a zonal (regional) PV structure with 6 cent-
ers, in consonance with its geopolitical set-up, which are linked to the 
National Pharmacovigilance Centre in the capital city Abuja. A PV pol-
icy document has just been launched to guide PV activities in the country.
The main thrust of the PV activities is the sensitization of the gen-
eral population and health care providers to raise the level of aware-
ness, as well as further advocacy of supervising regulatory bodies to 
ensure improved role of professionals and other stakeholders in PV. 
The current challenges include the engagement of the pharmaceutical 
industries, local and international, and the practitioners in herbal 
medicine. Again, coverage of the pediatric and geriatric population 
has also come into view.
In all, PV has made tremendous progress in Nigeria in the decade 
since its membership in the WHO international monitoring network.
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Most medicines in Europe are not authorized for use in children: 
almost 50% of medicines prescribed to children in the hospital are 
unlicensed for their age group or prescribed off-label. There are major 
practical and ethical issues in relation to studying medicines in chil-
dren, especially in neonates. To improve the situation, a pediatric 
regulation entered into force in 2007, and the European Medicines 
Agency identified drugs as priority medicinal products for evalua-
tion in children. The TINN project was selected by the FP7 program 
to evaluate ciprofloxacin and fluconazole. It was launched in 2008, 
and data evaluating ciprofloxacin are presented. Ciprofloxacin is a 
fluoroquinolone for the treatment of multiresistant gram-negative 
bacterial sepsis with an acceptable safety profile and a useful pattern 
of bacterial susceptibility. The TINN project included: (1) a litera-
ture review on ciprofloxacin in pediatric patients2; (2) juvenile animal 
studies using Phenopus3; and (3) a survey in Europe included 193 
NICUs from 32 countries. (4) Results showed that ciprofloxacin is 
used in 25% of NICUs, but indications and dosages vary widely4; a 
ciprofloxacin method was developed in low sample volumes5; (5) a 
population pharmacokinetic study (Liverpool, United Kingdom and 
Paris, France) included 51 neonates, showing that ciprofloxacin clear-
ance was dependent on current weight, gestational and postnatal age, 
and renal function and that volume of distribution was dependent of 
current weight6. A PIP for ciprofloxacin was not validated and no 
Paediatric-Use Marketing Authorisation (PUMA) will be obtained 
because the studies required were not possible to perform and the 
market is too small to expect viability of a new formulation. However, 
the studies conducted within TINN allow dosage recommendations to 
treat suspected or proven resistant gram-negative infections.
Project coordinated by the National Institute for Health and 
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